INS and type 1 diabetes mellitus: Eligible participants were patients aged 14 years and older with T1DM who had been on one of the following regimens for at least six months: a sensor-augmented insulin pump (MiniMed 640G or 740G, Medtronic, Dublin, Ireland), an insulin pump without a sensor (Paradigm VEO 754, Medtronic), or multiple daily insulin injections (MDIs).